| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
MSOP manufacturers
- MSOP
-
- $522.00
-
2026-07-15
- CAS:66515-29-5
- Purity:
- Supply Ability: 10g
|
| Product Name: | MSOP | | Synonyms: | MSOP;(RS)-ALPHA-METHYLSERINE-O-PHOSPHATE;(R,S)-a-Methylserine-O-phosphate;(RS)-α-Methylserine-O-phosphate;Serine, 2-methyl-O-phosphono-;2-Methyl-O- phosphonoserine;MSOP, group III metabotropic glutamate receptor antagonist | | CAS: | 66515-29-5 | | MF: | C4H10NO6P | | MW: | 199.1 | | EINECS: | | | Product Categories: | Glutamate receptor | | Mol File: | 66515-29-5.mol |  |
| Boiling point | 454.0±55.0 °C(Predicted) | | density | 1.681±0.06 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | H2O: soluble3mg/mL, clear (warmed) | | form | powder | | pka | 1.66±0.10(Predicted) | | color | white to beige | | Water Solubility | Soluble to 100 mM in water |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 |
| Uses | MSOP is a selective antagonist of group III mGlu receptors. | | Biological Activity | MSOP is a selective group III metabotropic glutamate receptor antagonist. Displays an apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR on primary afferent terminals in spinal cord compared to > 700 μM for the (1S,3S)-ACPD-sensitive presynaptic mGlu in the same system. Has no activity on postsynaptic mGlu receptors or on ionotropic glutamate receptors on neonatal rat motoneurons. | | in vivo | It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F3,16=30.96, P<0.001; CFA model: F3,16=30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group[2]. | | storage | Store at RT |
| | MSOP Preparation Products And Raw materials |
|